Curis Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Lexington MA United States (2000)

Organization Overview

First Clinical Trial
2000
NCT00004487
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Curis, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 1)

Brain Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Gastroesophageal Reflux (Phase 3)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Head and Neck Neoplasms (Phase 1)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Liver Neoplasms (Phase 1)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Medulloblastoma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 1)

Neuroblastoma (Phase 1)

Preleukemia (Phase 1)

Stomach Neoplasms (Phase 1)

Syndrome (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Vesico-Ureteral Reflux (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 14